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Abstract
Stauffer syndrome is a rare paraneoplastic syndrome classically associated with renal cell
carcinoma (RCC). This association gave it the historical name of nonmetastatic nephrogenic
hepatic dysfunction syndrome without jaundice. It is a syndrome of unclear pathophysiology
characterized by a reversible anicteric elevation of liver enzymes, alkaline phosphatase,
erythrocyte sedimentation rate (ESR), thrombocytosis, prolongation of prothrombin time, and
hepatosplenomegaly in the absence of direct hepatobiliary obstruction or jaundice. A rare
atypical variant of this syndrome with jaundice has been recently described in the literature.
Thus, it is important to consider both these variants of Stauffer syndrome in the differential
diagnosis of unexplained cholestasis in the absence of hepatic metastasis. This may allow early
recognition and treatment of an occult malignancy. Herein, we present a comprehensive review
of the literature available on the icteric variant of the Stauffer syndrome, outlining its
association with various malignancies and the diagnostic challenges it poses. The objective of
this review is to help clinicians in its early diagnosis and management.
Categories: Gastroenterology, Nephrology, Internal Medicine
Keywords: stauffer syndrome, renal cell carcinoma, paraneoplastic syndrome, paraneoplastic
hepatopathy
Introduction And Background
Stauffer syndrome, also known as Block‐Stauffer‐Rothmand's Syndrome, Thomson‐Rothmand's
Syndrome, ‘nephrogenous hepatosplenomegaly’ or ‘nephrogenous hepatic dysfunction’ was
first described by an American gastroenterologist Maurice H. Stauffer in 1961. He noted that
patients suffering from renal cell carcinoma (RCC) had abnormal liver function tests,
hepatosplenomegaly, and nonspecific hepatitis type histologic changes in the absence of
hepatic metastasis. Interestingly, tumor removal led to the reversal of these abnormalities [1].
This led to the conclusion that hepatic dysfunction in these patients was of a paraneoplastic
nature. This syndrome has been classically described in relation to the early stages of renal cell
cancer, but over time, literature has emerged supporting its association with other cancers
including bronchogenic carcinoma, bladder cancer, pancreatic cancer, metastatic prostate
adenocarcinoma, soft tissue sarcoma, and malignant lymphoproliferative diseases.
Review
The term paraneoplastic syndrome refers to a constellation of systemic signs and symptoms
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that are secondary to malignancy and does not include the sequelae of either direct tumor
extension or metastasis. They are believed to be the result of the following processes: i)
production of humoral substances by tumor cells, ii) production of humoral factors in response
to malignancy by benign tissues, or iii) via immune system modulation [1].
A review of all the available data, published in the English language, yielded more than 100
cases of Stauffer syndrome since it was first described in 1961. Most cases are described in
association with RCC, with an incidence of 3%-6% among these patients [2]. Prostate cancer
was a close second followed by soft tissue sarcomas [3], pancreatic cancer, bladder cancer [4],
malignant lymphoproliferative diseases [5], and isolated cases with bronchogenic
carcinoma [6], gastrointestinal carcinoid [7], and one case report with a thrombocytopenia
variant [8]. A vast majority of cases are of classical nature, and only a handful of jaundice
variants have been reported to date, as detailed in Table 1. In 1997, the first two cases of
jaundice variant were described by Dourakis et al. in association with RCC [9]. These variant
cases can present with hyperbilirubinemia, urinary hyperpigmentation, hepatosplenomegaly,
jaundice, and/or pruritus along with the classical findings of elevated liver function tests
(LFTs), erythrocyte sedimentation rate (ESR), alpha-2 globulin, platelets, and prothrombin
time [2].
Malignancy
associated with
Stauffer
syndrome
jaundice variant
References (Author, Year of publication, Ref. )
Renal cell
carcinoma  
Mazokopakis and Papadakis (2007) [2], Dourakis et al. (1997) [9], Morla et al. (2006) [6], Akbulut et
al. (2014) [10], Giannakos et al. (2005) [11], Sarf et al. (2003) [12], Tomadoni et al. (2010) [13],
Fernandez and de Ávila (2012) [14], Jangouk and  Hashash (2014) [15], Puga et al. (2015) [16],
Ates et al. (2015) [8], Current report (2019)
Prostate
carcinoma 
Kato et al. (2014) [17], Kuramoto et al. (2013) [18], Hinostroza-Yanahuaya et al. (2013) [19],
Bhangoo et al. (2018) [20], Ravindranathan et al. (2018) [21], Gokcen et al. (2019) [22], Romasovs
et al. (2019) [23]
Pancreatic cancer Harris and Saif (2017) [4]
Gastrointestinal
carcinoid Mehta (2017) [7]
TABLE 1: Published case reports of icteric variant of Stauffer syndrome with
corresponding type of cancer.
Paraneoplastic hepatopathy typically consists of unexplained elevation in liver enzymes, with
or without jaundice, without the evidence of anatomic obstruction of bile flow, infectious
etiology, or neoplastic involvement of the liver or bile ducts. The resolution of hepatopathy is
noted after successful chemotherapy or surgical treatment of the primary tumor. One theory
explaining the mechanism of paraneoplastic liver dysfunction suggests the release of either a
humoral substance or lysosomal enzymes from the tumor, with distant effects on the liver and
hematopoietic system. An increase in lysosomal enzyme activity in liver cells of patients with
renal carcinoma has supported this theory. Additional speculated mechanisms include
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generalized hepatic hypervascularity seen on angiography, hepatic amyloid deposition,
nonspecific focal periportal inflammation on liver biopsy, or an autoimmune phenomenon
directed against a tumor antigen which cross-reacts with a liver protein involved in hepatic
bilirubin transport [24]. Elevated IL-6 appears to be a recurring theme of Stauffer syndrome
with its presence reported in a majority of cases in the literature. Blay et al. documented that
patients with RCC and elevated alkaline phosphatase have significantly higher levels of serum
IL-6 [15, 25]. Bhangoo et al. suggested the association of IL-6 and cholestasis may be mediated
by a systemic inflammation as laboratory markers including C-reactive protein (CRP) and
haptoglobin are elevated in these patients. These pro-inflammatory cytokines inhibit
expression of the hepatobiliary transporter gene expression, possibly explaining impaired
biliary outflow [20]. A study conducted by Karakolio et al. found that treatment with anti-
interleukin 6 monoclonal antibody reversed most of the biochemical abnormalities of patients
with Stauffer syndrome [5]. Hence, it can be concluded that IL-6 plays a central role in the
pathogenesis of Stauffer syndrome. This also explains why patients with elevated levels of
serum IL‐6 and CRP have elevated levels of haptoglobin, bilirubin, gamma glutamyl‐
transferase, platelets, polymorphonuclear neutrophils (PMN), and alkaline phosphatase. It is
also seen that in patients with serum IL‐6 over 80 pg/mL (normal: < 5 pg/mL), hemoglobin
levels are found to be significantly lower than in patients with low/undetectable serum IL-6
levels [11]. The exact pathophysiology is yet to be determined [15].
Elevated alkaline phosphatase is the most common laboratory finding seen in approximately
90% of Stauffer syndrome cases. Elevated transaminases and hyperbilirubinemia are seen in
21% and 15% of cases, respectively [15]. A typical patient will have an anicteric presentation but
an atypical variant with jaundice has also been described in the literature [1]. Other laboratory
abnormalities include elevation of ESR, alpha-2-globulin, gamma-glutamyl transferase,
thrombocytosis, and prolongation of prothrombin time [1, 6]. With these findings, patients are
often worked up for a hepatic source. Investigations include serological tests for viral hepatitis
A, B, C, δ, cytomegalovirus (CMV), Epstein‐Barr virus, Herpes virus, HIV, leptospirosis, and
immunological assays for autoimmune diseases (antinuclear antibody, antimitochondrial
antibody, anti-smooth muscle antibody, anti dsDNA, anti ssDNA, anti-histone antibody, p‐
ANCA, c‐ANCA, Ra‐factor) [11]. In addition, iron studies, serum ceruloplasmin level, and alpha-
fetoprotein levels are also performed to rule out metabolic causes and primary hepatic
cancer [6]. Upper abdominal ultrasound is usually within normal limits or can show a
marginally increased echogenicity and size of the liver parenchyma, without any dilatation of
intra‐ or extra‐hepatic bile ducts or any other sign of localized lesions. Endoscopic retrograde
cholangiopancreatography (ERCP) and magnetic resonance cholangiopancreatography (MRCP)
are often within normal limits [25]. Liver biopsy will reveal cholestasis with occasional
nonspecific infiltration by neutrophils, lymphocytes, monocytes, and rarely granulomas [4, 11].
With such an extensive workup often unrevealing of any evidence of known hepatic pathology,
physicians must consider the possibility of cholestasis as a paraneoplastic presentation and
should directly focus on unmasking an underlying occult malignancy. Ultrasonography can
have certain pitfalls in detecting RCC and isoechoic RCC could be missed in routine abdominal
ultrasonography [26]. CT abdomen or MRI is a more sensitive modality to locate a tumor. 
The treatment of Stauffer syndrome is directed towards the treatment of underlying
malignancy. Surgical removal of an otherwise local cancer via nephrectomy leads to dramatic
and complete resolution of hepatic abnormalities [4]. Recurrence of liver enzyme abnormalities
in conjunction with tumor recurrence has been reported as well. However, this syndrome must
be differentiated from jaundice caused by metastatic infiltration of the liver, which carries a
considerably worse prognosis [5].
Conclusions
Stauffer syndrome is an uncommon but important paraneoplastic manifestation of RCC and
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other malignancies. Clinicians should be aware of RCC's propensity to present as a broad
spectrum of nonrenal manifestations and should have a high index of suspicion when
encountered with unexplained liver abnormalities with or without jaundice. Appropriate
imaging studies should be performed to make an early diagnosis and increase the likelihood of
operative success. Treatment of underlying malignancy appears to resolve hepatic
abnormalities. 
Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors
declare the following: Payment/services info: All authors have declared that no financial
support was received from any organization for the submitted work. Financial relationships:
All authors have declared that they have no financial relationships at present or within the
previous three years with any organizations that might have an interest in the submitted work.
Other relationships: All authors have declared that there are no other relationships or
activities that could appear to have influenced the submitted work.
References
1. Palapattu GS, Kristo B, Rajfer J: Paraneoplastic syndromes in urologic malignancy: the many
faces of renal cell carcinoma. Rev Urol. 2002, 4:163-170.
2. Mazokopakis E, Papadakis J, Kofteridis D: Unusual causes of intrahepatic cholestatic liver
disease. World J Gastroenterol. 2007, 13:1879-1882.
3. Fontes-Sousa M, Magalhães H, da Silva F, Maurício MJ: Stauffer’s syndrome: a comprehensive
review and proposed updated diagnostic criteria. Urol Oncol. 2018, 36:321-326.
4. Harris D, Saif M: Stauffer’s syndrome in pancreatic cancer: first case report . Cureus. 2017, 9:5.
5. Karakolio A, Kasapisa C, Kallinikidisa T, Kalpidis P, Grigoriadis N: Cholestatic jaundice as a
paraneoplastic manifestation of prostate adenocarcinoma. Clin Gastroenterol Hepatol. 2003,
6:480-483.
6. Morla D, Alazemi S, Lichtstein D: Stauffer's syndrome variant with cholestatic jaundice: a
case report. J Gen Intern Med. 2006, 21:11-13. 10.1111/j.1525-1497.2006.00448.x
7. Mehta D, Chugh P, Chawla L, Jodorkovsky D: Paraneoplastic hepatopathy associated with
gastrointestinal carcinoid. ACG Case Rep J. 2017, 4:117. 10.14309/crj.2017.117
8. Ateş İ, Kaplan M, Yılmaz N: A Stauffer's syndrome variant associated with renal cell
carcinoma and thrombocytopenia. Afr J Urol. 2015, 21:217-219.
9. Dourakis S, Sinani C, Deutsch M, Dimitriadou E, Hadziyannis SJ: Cholestatic jaundice as
paraneoplastic manifestation of renal cell carcinoma. Eur J Gastroenterol Hepatol. 1997,
9:311-314.
10. Akbulut S, Baysal A, Topal F: Paraneoplastic presentation of cholestatic jaundice in renal cell
carcinoma. Turk J Gastroenterol. 2014, 25:340-341.
11. Giannakos G, Papanicolaou X, Trafalis D, Michaelidis I, Margaritis G, Christofilakis C:
Stauffer's syndrome variant associated with renal cell carcinoma . Int J Urol. 2005, 12:757-759.
12. Sarf I, el Mejjad A, Dakir M, Meziane A, Badre L, Aboutaieb R, Meziane F: [Stauffer syndrome
associated with a giant renal tumor]. Prog Urol. 2003, 13:290-292.
13. Tomadoni A, García C, Márquez M, Ayala JC, Prado F: Stauffer's syndrome with jaundice, a
paraneoplastic manifestation of renal cell carcinoma: a case report. Arch Esp Urol. 2010,
63:154-156.
14. Fernández AB, de Ávila AS: Prothrombin complex concentrate (Octaplex®) for postsurgical
bleeding control in a Stauffer's syndrome. Ann Hematol. 2012, 91:1325-1326. 10.1007/s00277-
011-1396-8
15. Jangouk P, Hashash J: An unusual case of painless jaundice . Gastroenterology. 2014, 146:4.
16. Puga M, Gonzalez-Ballina E, Rivas-Moral L: Stauffer’s syndrome variant as an unusual case of
painless jaundice. Clin Gastroenterol Hepatol. 2015, 13:A25-A26.
17. Kato D, Okwara C, Moreland C, Parker A: Hepatic dysfunction as a paraneoplastic
manifestation of metastatic prostate adenocarcinoma. J Investig Med High Impact Case Rep.
2019 Sharma et al. Cureus 11(10): e6032. DOI 10.7759/cureus.6032 4 of 5
2014, 2:2324709614539927. 10.1177/2324709614539927
18. Kuramoto T, Senzaki H, Koike H, Yamagiwa K, Tamura S, Fujimoto T, Inagaki T: Case report:
cholestatic jaundice as a paraneoplastic manifestation of prostate cancer. Case Rep Urol. 2013,
2013:303727. 10.1155/2013/303727
19. Hinostroza-Yanahuaya J, Mon-Mon C, Ortega-Marcos O, Herrero-Berron JC, Ortiz-Libreros M,
Vigil-Medina A: Stauffer syndrome and prostate carcinoma, two cases in chronic
haemodialysis patients. Nefrologia. 2013, 33:749-750.
20. Bhangoo M, Cheng B, Botta G, Thorson P, Kosty MP: Reversible intrahepatic cholestasis in
metastatic prostate cancer: an uncommon paraneoplastic syndrome. Mol Clin Oncol. 2018,
8:613-616.
21. Ravindranathan D, Hitron E, Russler G, Xue Y, Bilen MA: Metastatic prostate cancer
manifesting as cholestatic jaundice: a case report and review of the literature. Case Rep Oncol
Med. 2018, 26:1809432.
22. Gökçen P, Gökçen K, Çakmak E, Gökçe G: Paraneoplastic hyperbilirubinemia in metastatic
prostate cancer and review of the current literature. Turk J Urol. 2019, 45:70-72.
23. Romašovs A, Puķītis A, Mokricka V, Frolova E: Stauffer's syndrome in a patient with
metastatic prostate cancer. Case Reports Urol. 2019, 2019: 10.1155/2019/9745301
24. Sharara A, Panella T, Fitz J: Paraneoplastic hepatopathy associated with soft tissue sarcoma .
Gastroenterology. 1992, 103:330-332.
25. Blay J, Rossi J, Wijdenes J, et al.: Role of Interleukin-6 in the paraneoplastic inflammatory
syndrome associated with renal cell carcinoma. Int J Cancer. 1997, 72:424-430.
26. Fonseka C, Kariyawasam A, Singhapura S, et al.: Metastatic renal cell carcinoma presenting as
prolonged pyrexia and Stauffer’s syndrome: can a routine ultrasound scan fails to detect a
renal cell carcinoma?. Case Rep Radiol. 2018, 2018:4215041. 10.1155/2018/4215041
2019 Sharma et al. Cureus 11(10): e6032. DOI 10.7759/cureus.6032 5 of 5
